Procter & Gamble holds steady despite cost pressures and cautious FY26 outlook amid inflation and competition.

Procter & Gamble reported a solid Q3 FY26 with 3% organic sales growth and $1.59 adjusted EPS, supported by strong free cash flow. However, rising costs linked to the Middle East conflict and commodity inflation are pressuring margins. The company’s FY26 guidance is cautious, expecting 1%-5% sales growth and EPS near the lower end of $6.83-$7.09. Long-term challenges include competition from private labels and ongoing inflation, which may impact volumes, margins, and valuations, leading analysts to maintain a Hold rating due to limited valuation safety.